Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum Biomarkers in Diagnosis and Clinical Management of Inflammatory Bowel Disease: Anything New on the Horizon

J. Ondriš, R. Husťak, J. Ďurina, E. Malicherová Jurková, V. Bošák

. 2024 ; 70 (5-6) : 248-261. [pub] -

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc25005463

Persistent inflammation in inflammatory bowel disease (IBD) leads to progressive damage to the gastrointestinal tract, resulting in potentially severe sequelae. Diagnosis primarily relies on invasive endoscopy and monitoring of faecal calprotectin (FC), which has limitations, particularly regarding patient compliance. There is a pressing need for a new biomarker that is non-invasive, easily determinable, and possesses good diagnostic accuracy for both dia-gnosing and monitoring IBD. Our narrative review covers the latest developments in novel serum biomarkers, focusing on those with promising diagnostic accuracy and laboratory methods, and evaluates them in the context of established biomarkers such as FC and CRP. Serum calprotectin (SC) and leucine-rich alpha-2 glycoprotein (LRG) show the most extensive evidence and relatively good diagnostic accuracy but currently cannot replace FC due to insufficient evidence. Major limitations of the analysed studies include their monocentric nature, small sample sizes, lack of longitudinal monitoring and in some cases, missing assessments of endoscopic activity. ELISA holds a leading position among the laboratory methods; however, emerging evidence supports the potential use of point-of-care testing (POCT). Establishing these biomarkers for regular clinical application will require further validation through multicentric studies involving a larger number of patients with a longitudinal design, concurrent assessment of endoscopic activity and pro-active monitoring of the biomarker. However, based on the evidence accumulated so far, SC might potentially serve as a complementary biomarker and/or in assessing the activity of extraintestinal manifestations in IBD patients, while LRG appears to be effective in evaluating endoscopic activity, especially in small bowel CD.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25005463
003      
CZ-PrNML
005      
20250521143030.0
007      
ta
008      
250213s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.14712/fb2024070050248 $2 doi
035    __
$a (PubMed)39889217
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Ondriš, Juraj $u AstraZeneca AB o.z., Bratislava, Slovakia. ondris.j@gmail.com $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia. ondris.j@gmail.com $7 _AN122526
245    10
$a Serum Biomarkers in Diagnosis and Clinical Management of Inflammatory Bowel Disease: Anything New on the Horizon / $c J. Ondriš, R. Husťak, J. Ďurina, E. Malicherová Jurková, V. Bošák
520    9_
$a Persistent inflammation in inflammatory bowel disease (IBD) leads to progressive damage to the gastrointestinal tract, resulting in potentially severe sequelae. Diagnosis primarily relies on invasive endoscopy and monitoring of faecal calprotectin (FC), which has limitations, particularly regarding patient compliance. There is a pressing need for a new biomarker that is non-invasive, easily determinable, and possesses good diagnostic accuracy for both dia-gnosing and monitoring IBD. Our narrative review covers the latest developments in novel serum biomarkers, focusing on those with promising diagnostic accuracy and laboratory methods, and evaluates them in the context of established biomarkers such as FC and CRP. Serum calprotectin (SC) and leucine-rich alpha-2 glycoprotein (LRG) show the most extensive evidence and relatively good diagnostic accuracy but currently cannot replace FC due to insufficient evidence. Major limitations of the analysed studies include their monocentric nature, small sample sizes, lack of longitudinal monitoring and in some cases, missing assessments of endoscopic activity. ELISA holds a leading position among the laboratory methods; however, emerging evidence supports the potential use of point-of-care testing (POCT). Establishing these biomarkers for regular clinical application will require further validation through multicentric studies involving a larger number of patients with a longitudinal design, concurrent assessment of endoscopic activity and pro-active monitoring of the biomarker. However, based on the evidence accumulated so far, SC might potentially serve as a complementary biomarker and/or in assessing the activity of extraintestinal manifestations in IBD patients, while LRG appears to be effective in evaluating endoscopic activity, especially in small bowel CD.
650    _2
$a lidé $7 D006801
650    12
$a biologické markery $x krev $7 D015415
650    12
$a idiopatické střevní záněty $x krev $x diagnóza $7 D015212
650    _2
$a leukocytární L1-antigenní komplex $x krev $7 D039841
650    _2
$a feces $x chemie $7 D005243
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Husťak, Rastislav $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia $u Gastroenterology Department, Clinic of Internal Medicine, University Hospital in Trnava, Slovakia $7 xx0229151
700    1_
$a Ďurina, Juraj $u Gastroenterology and Hepatology Centre, University Hospital with Polyclinic in Nové Zámky, Slovakia $7 xx0077155
700    1_
$a Jurková Malicherová, Eva $u Centre for Periodic Fever Syndromes, Department of Paediatrics, Jessenius Faculty of Medicine of Comenius University in Bratislava and University Hospital in Martin, Slovakia $7 xx0238239
700    1_
$a Bošák, Vladimír $u Department of Laboratory Medicine, Faculty of Health Care and Social Work, Trnava University, Trnava, Slovakia $7 xx0128493
773    0_
$w MED00011004 $t Folia biologica $x 0015-5500 $g Roč. 70, č. 5-6 (2024), s. 248-261
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39889217 $y Pubmed
910    __
$a ABA008 $b A 970 $c 89 $y p $z 0
990    __
$a 20250213 $b ABA008
991    __
$a 20250521143028 $b ABA008
999    __
$a ok $b bmc $g 2324836 $s 1242483
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 70 $c 5-6 $d 248-261 $e - $i 0015-5500 $m Folia biologica $n Folia Biol (Praha) $x MED00011004
LZP    __
$b NLK116 $a Pubmed-20250213

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...